The anatomical and functional outcomes and intraoperative complications of 20 gauge vs 23 gauge pars plana vitrectomy combined with phacoemulsification following intravitreal bevacizumab in diabetic tractional retinal detachment

Retina-Vitreus

Volumn 18, Issue 2, 2010, Pages 122-128

  Güngel, Hülya ^a   Altan, Çiǧdem ^a   Oygar Baylançiçek, Deniz ^b  

^a Beyoglu Eye Training and Research Hospital   (Turkey)

^b NONE

Author keywords

20 Gauge pars plana vitrectomy; 23 Gauge microincision PPV; Fractional retinal detachment; Intravitreal bevacizumab

Indexed keywords

BEVACIZUMAB; OFLOXACIN;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; HUMAN; IRIS RUBEOSIS; PEROPERATIVE COMPLICATION; PHACOEMULSIFICATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; REOPERATION; RETINA DETACHMENT; RETINA TEAR; VISUAL ACUITY; VITRECTOMY;

EID: 77954608479     PISSN: 13001256     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Oshima Y, Shima C, Wakabayashi T, et al.: Microincisionvitrectomy surgery and intravitrealbevacizumab as a surgical adjunct to treat diabetic traction retina detachment Ophthalmology. 2009;116:927-938.
2. Eckardt C.: Transconjunctivalsutureless 23-gauge vitrectomy. Retina. 2005;25:208-211.
3. Chen E, Park C.: Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferatif diabetik retinopathy. Retina. 2006;26:699-700. (Pubitemid 44620378)
4. Avery R, Pearlman J, Piemarici D, et al.: Intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy. Ophtalmology. 2006;113:1695-1705.
5. Spaide R, Fisher Y.: Intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy comlicated by vitreus haemorrhage. Retina. 2006;26:275-278.
6. Mason J, Nixon P, White M.: Intravitreal injection of bevacizumab as adjunctive the treatment of proliferative diabetic retinopathy. Am J Ophtalmol. 2006;142:685-688.
7. Isaacs T, Barry C.: Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab. Clin Experiment Ophtalmol. 2006;34:802-805.
8. Chen JC.: Sutureless pars plana vitrectomy through self-sealing sclerotomies. Arch Ophthalmol. 1996;114:1273-1275. (Pubitemid 26338863)
9. Fine HF, Iranmanesh R, Iturralde D, et al.: Outcomes of 77 consecutive cases of 23-gauge transconjunctival vitrectomy surgery for posterior segment disease. Ophthalmology. 2007;114:1197-1200.
10. Gupta OP, Ho A C, Kaiser PK, et al.: Short term outcomes of 23-gauge Pars plana vitrectomy. Am J Ophthalmol. 2008;146:193-197.
11. Wimpissinger B, Kellner L, Brannath W, et al.: 23 Gauge versus 20 gauge system for pars plana vitrectomy: a prospective randomised clinical trial. Br J Ophthalmol. 2008;92:1483-1487.
12. Misra A, Ho-Yen G, Burton RL.: 23 gauge sutureless vitrectomy and 20 gauge vitrectomy: a case series comparison. Eye. 2009; 23:1187-1191.
13. Chung TY, Chung H, Lee JH.: Combined surgery and sequential surgery comprising phacoemulsification, pars plana vitrectomy, and intraocular lens implantation: Comparison of clinical outcomes. J Cataract Refract Surg. 2002;28:2001-2005.
14. Demetriades AM, Gottsch JD, Thomsen R, et al.: Combined phacoemulsification, intraocular lens implantation, and vitrectomy for eyes with coexisting cataract and vitreoretinal pathology. Am J Ophthalmol. 2003;135:291-296. (Pubitemid 36279513)
15. Lam DSC, Young AL and Rao SK, et al.: Combined phacoemulsification, pars plana vitrectomy, and foldable intraocular lens implantation. J Cataract Refract Surg. 2003;29:1064-1069. (Pubitemid 36759093)
16. Jun Z, Pavlovic S, Jacobi KW.: Results of combined vitreoretinal surgery and phacoemulsification with intraocular lens implantation. Clin Experiment Ophthalmol. 2001;29:307-311. (Pubitemid 33039844)
17. de Bustros S, Thompson JT and Michels RG, et al.: Nuclear sclerosis after vitrectomy for idiopathic epiretinal membranes. Am J Ophthalmol. 1998;105:160-164.
18. L. Cheng S, Azen P and El-Bradey MH et al.: Duration of vitrectomy and postoperative cataract in the vitrectomy for macular hole study. Am J Ophthalmol. 2001;132:881-887.
19. Melberg NS and Thomas MA.: Nuclear sclerotic cataract after vitrectomy in patients younger than 50 years of age. Ophthalmology. 1995;102:1466-1471.
20. Faulborn JBP, Conway and Machemer R.: Surgical complications of pars plana vitreous surgery. Ophthalmology. 1978;85:116-125.
21. Koch F, Kloss KM, Hockwin O, et. al.: Lens changes following intraocular tamponade in vitrectomy: Linear densitometric image analysis of Scheimpflug photographs 6 months after operation. Klin Monatsbl Augenheilkd. 1991;199:8-11.
22. Theelen T, Verbeek AM, Tilanus MA, et al.: A novel technique for self-sealing, wedge-shaped pars plana sclerotomies and its features in ultrasound biomicroscopy and clinical outcome. Am J Ophthalmol. 2003;136:1085-1092. (Pubitemid 37485775)
23. Kadonosono K, Matsumoto S and Uchio E, et al.: Iris neovascularization after vitrectomy combined with phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy . Ophthalmic Surg Lasers. 2001;32:19-24. (Pubitemid 32113335)
24. Scharwey K, Pavlovic S and Jacobi KW.: Combined clear corneal phacoemulsification, vitreoretinal surgery, and intraocular lens implantation. J Cataract Refract Surg. 1999;25:693-698. (Pubitemid 29222601)
25. Lahey JM, Francis RR and Kearney JL.: Combining phacoemulsification with pars plana vitrectomy in patients with proliferative diabetic retinopathy: a series of 223 cases. Ophthalmology. 2003;110:1335-1339.
26. Schatz H, Atienza D, McDonald HR.: Severe diabetic retinopathy after cataract surgery. Am J Ophthalmol. 1994;117:314-321. (Pubitemid 24081416)
27. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al.: Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008; 246:837-842.
28. Thompson JT, Auer CL, de Bustros S, et al.: Prognostic indicators of success and failure in vitrectomy for diabetic retinopathy. Ophthalmology. 1986;93:290-295.
29. Yorston D, Wickam L, Benson S, et al.: Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:365-368. (Pubitemid 351363532)
30. La Heij EC, Tecim S, Kessels AG, et al.: Clinical variables and their relation to visual outcome after vitrectomy in eyes with diabetic retinal traction detachment. Graefes Arch Clin Exp Ophthalmol. 2004;242:210-217. (Pubitemid 38477206)
31. la R Lucena D, Riberio JA, Costa RA, et al.: Intraoperative bleeding during vitrectomy for diabetic fractional retinal detachment with versus without preoperative intravitreal bevacizumab. Br J Ophthalmol. 2009;93:688-691.
32. Yeoh J, Williams C, Allen P, et al.: Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol. 2008;36:449-454.
33. Yang CM, Yeh PT, Yang CH, et al.: Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol. 2008;146:211-217.
34. Yeung L, Liu L, Wu WC, et al.: Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic fractional retinal detachment. Acta Ophthalmol 2009;4.
35. Mosesson, MW.: Fibrinogen and fibrin structure and function. J Thromb Haemost. 2005;3:1894-1904.
36. The diabetic retinopathy vitrectomy study research group: Early vitrectomy for severe proliferative diabetic retinopathy in eyes with usefull vision. Clinical application of result of a randomized trial. DRVS report 4. Ophthalmology. 1988;95:1321-1334.
37. Arevalo JF, Maia M, Flynn HW Jr, et al.: Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213-216. (Pubitemid 351224097)
38. Ishikawa K, Honda S, Tsukahara Y, et al.: Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye. 2009;23:108-111.
39. Oshima Y, Sakaguch H , Gomi F, et al.: Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-158.
40. Avery RL.: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:352-354. (Pubitemid 44318195)
41. Heiduschka P., Fietz H. and Hofmeister S., et al.: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-2823. (Pubitemid 351261238)